CA2795438A1 - Method of detecting and profiling progression of the risk of neurodegenerative diseases - Google Patents
Method of detecting and profiling progression of the risk of neurodegenerative diseases Download PDFInfo
- Publication number
- CA2795438A1 CA2795438A1 CA2795438A CA2795438A CA2795438A1 CA 2795438 A1 CA2795438 A1 CA 2795438A1 CA 2795438 A CA2795438 A CA 2795438A CA 2795438 A CA2795438 A CA 2795438A CA 2795438 A1 CA2795438 A1 CA 2795438A1
- Authority
- CA
- Canada
- Prior art keywords
- stem cell
- determining
- antibody
- subject
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 55
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 51
- 210000000130 stem cell Anatomy 0.000 claims abstract description 69
- 238000007069 methylation reaction Methods 0.000 claims abstract description 39
- 230000011987 methylation Effects 0.000 claims abstract description 35
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 13
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims description 19
- 108010033040 Histones Proteins 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 15
- 102000006947 Histones Human genes 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 9
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 9
- 101150008375 Pou4f1 gene Proteins 0.000 claims description 9
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- -1 TuJ1 Proteins 0.000 claims description 8
- 239000002771 cell marker Substances 0.000 claims description 7
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 6
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 229940064128 l-methylfolate Drugs 0.000 claims description 3
- 235000007635 levomefolic acid Nutrition 0.000 claims description 3
- 239000011578 levomefolic acid Substances 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 5
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 28
- 239000000523 sample Substances 0.000 description 17
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 16
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 16
- 210000001178 neural stem cell Anatomy 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 210000000276 neural tube Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 5
- 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000010193 neural tube defect Diseases 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006097 Spinal Dysraphism Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000007630 basic procedure Methods 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000001982 neural crest cell Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002023 somite Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 1
- 101100516508 Mus musculus Neurog2 gene Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 102000055601 Nanog Homeobox Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 description 1
- 101710198368 POU domain, class 4, transcription factor 1 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101000713578 Rattus norvegicus Tubulin beta-3 chain Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 230000001928 neurorestorative effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39532110P | 2010-05-11 | 2010-05-11 | |
| US61/395,321 | 2010-05-11 | ||
| PCT/US2011/033387 WO2011142952A1 (en) | 2010-05-11 | 2011-04-21 | Method of detecting and profiling progression of the risk of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2795438A1 true CA2795438A1 (en) | 2011-11-17 |
Family
ID=44914644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795438A Abandoned CA2795438A1 (en) | 2010-05-11 | 2011-04-21 | Method of detecting and profiling progression of the risk of neurodegenerative diseases |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130029998A1 (https=) |
| EP (1) | EP2569625A4 (https=) |
| JP (1) | JP2013526705A (https=) |
| CA (1) | CA2795438A1 (https=) |
| WO (1) | WO2011142952A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7118886B2 (ja) | 2015-06-03 | 2022-08-16 | エアラン セル テクノロジーズ， インコーポレイテッド | 幹細胞からの有益因子の産生および送達のための方法およびデバイス |
| US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
| CN109415431A (zh) | 2016-04-20 | 2019-03-01 | 爱兰细胞技术公司 | 与k180二甲基化h1.0蛋白相关的组合物和方法 |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| CN111770761B (zh) | 2017-10-25 | 2024-07-09 | 爱兰细胞技术公司 | H1.0k180me2抗体、其制造方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7025A (en) * | 1850-01-15 | Buckle | ||
| US11016A (en) * | 1854-06-06 | Method of turning hubs | ||
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| CN101909630A (zh) * | 2007-11-02 | 2010-12-08 | 新加坡科技研究局 | 预防和治疗肿瘤的方法和化合物 |
| WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
-
2011
- 2011-04-21 JP JP2013510115A patent/JP2013526705A/ja active Pending
- 2011-04-21 EP EP11780997.0A patent/EP2569625A4/en not_active Withdrawn
- 2011-04-21 US US13/640,545 patent/US20130029998A1/en not_active Abandoned
- 2011-04-21 CA CA2795438A patent/CA2795438A1/en not_active Abandoned
- 2011-04-21 WO PCT/US2011/033387 patent/WO2011142952A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011142952A1 (en) | 2011-11-17 |
| EP2569625A1 (en) | 2013-03-20 |
| EP2569625A4 (en) | 2013-12-04 |
| US20130029998A1 (en) | 2013-01-31 |
| JP2013526705A (ja) | 2013-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease | |
| Gibbons et al. | Detection of Alzheimer disease (AD)-specific tau pathology in AD and nonAD tauopathies by immunohistochemistry with novel conformation-selective tau antibodies | |
| Hamilton et al. | Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer’s disease | |
| Nijholt et al. | The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies | |
| Rodríguez-Martín et al. | Tau phosphorylation affects its axonal transport and degradation | |
| Regad et al. | The tumor suppressor Pml regulates cell fate in the developing neocortex | |
| Aydemir et al. | The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study | |
| CN103154736B (zh) | 用于检测和诊断神经变性疾病的诊断性自身抗体谱 | |
| US20130029998A1 (en) | Method of Detecting and Profiling Progression of the Risk of Neurodegenerative Diseases | |
| Wenk et al. | Altered cholinergic function in the basal forebrain of girls with Rett syndrome | |
| Swenson et al. | Senescence in aging and disorders of the central nervous system | |
| EP1339743A2 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| JP5642687B2 (ja) | 神経学的な自己免疫性障害 | |
| Mazzetti et al. | Astrocytes expressing Vitamin D‐activating enzyme identify Parkinson’s disease | |
| Min et al. | Insulin‐like growth factor I regulates G2/M progression through mammalian target of rapamycin signaling in oligodendrocyte progenitors | |
| Melamud et al. | Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin‐4 expression and water permeability of the astrocyte plasma membrane | |
| Liu et al. | Calcium sensing receptor absence delays postnatal brain development via direct and indirect mechanisms | |
| Mukaetova-Ladinska et al. | Alpha-and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes | |
| Bernstein et al. | Partial loss of parvalbumin‐containing hippocampal interneurons in dementia with Lewy bodies | |
| Teunissen et al. | Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis | |
| Gong et al. | High fat diet aggravates AD-related pathogenic processes in APP/PS1 mice | |
| Costa et al. | Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease | |
| US20150025008A1 (en) | Compositions and Methods of Detecting and Treating Neural Tube Defects | |
| Iacono et al. | Reduced number of pigmented neurons in the substantia nigra of dystonia patients? Findings from extensive neuropathologic, immunohistochemistry, and quantitative analyses | |
| CN105277715A (zh) | 巨噬细胞迁移抑制因子(mif)作为早期阿尔茨海默病血清分子标志物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20160421 |